Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 9, 2026

Denali Therapeutics Inc. (DNLI)

A forensic read on Denali Therapeutics Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Grey Zone

Financial health

3.6

Distress distance

Forensic signals

-45.7%

ROE

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Denali Therapeutics Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 3.6, placing it in the Grey zone. 2 forensic signals were flagged in its latest SEC filings, led by share-count dilution.

What the filings flag

+12.1%/yr

FY2023–FY2025

Share-count dilution. Diluted share count changed +26% over the last 2 years to FY2025 (+12.1%/yr). The count is growing — 137.4M shares in FY2023, 172.6M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~12.1% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~20%.

-$1.1B

FY2023–FY2025

Cash burn vs. reported loss. Over FY2023–FY2025, the company reported a cumulative net loss of $1.1B against operating cash flow of -$1.1B. Cash burn ran heavier than the reported loss — something outside net income (working capital, a cash item not in the P&L) is consuming cash faster than the loss alone implies.

Key fundamentals

Free Cash Flow-$422.1M

Return on Equity-45.7%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Denali Therapeutics Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 9, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.